GLP-1 drugs eased a brutal skin disease more than the weight loss explains A June 15 systematic review in the American Journal of Clinical Dermatology pooled 19 studies and 67,568 patients and linked GLP-1 receptor agonists to real improvement in hidradenitis suppurativa, a painful inflammatory skin disease. Sixty percent of patients dropped at least one Hurley severity stage, quality-of-life scores improved by 3.83 points, and C-reactive protein and HbA1c both fell. The catch that makes it interesting: average BMI fell only 2.64 kg/m2, too little to explain the skin gains on its own, hinting the drugs' anti-inflammatory side is doing real work, though the mostly observational evidence cannot prove it.